These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38145442)

  • 1. The influence of a modified p53 C-terminal peptide by using a tumor-targeting sequence on cellular apoptosis and tumor treatment.
    Guo X; Zhang Y; Li Q; Shi F; HuangFu Y; Li J; Lao X
    Apoptosis; 2024 Jun; 29(5-6):865-881. PubMed ID: 38145442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.
    Zhang T; Wu K; Ding C; Sun K; Guan Z; Wang X; Hsieh JT; He D; Fan J
    Oncotarget; 2015 Nov; 6(35):37782-91. PubMed ID: 26462022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
    Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
    Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
    Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
    PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.
    Kondo E; Tanaka T; Miyake T; Ichikawa T; Hirai M; Adachi M; Yoshikawa K; Ichimura K; Ohara N; Moriwaki A; Date I; Ueda R; Yoshino T
    Mol Cancer Ther; 2008 Jun; 7(6):1461-71. PubMed ID: 18566217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGD and polyhistidine tumor homing peptides potentiates the action of human Maspin as an antineoplastic candidate.
    Yin R; Guo L; Zhang J; Liu G; Yao W; Zhu H; Xu X; Zhang W
    Appl Microbiol Biotechnol; 2016 Jul; 100(14):6209-6218. PubMed ID: 26846625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
    Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
    Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-specific p53 mutant reactivation.
    Yu X; Vazquez A; Levine AJ; Carpizo DR
    Cancer Cell; 2012 May; 21(5):614-625. PubMed ID: 22624712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
    Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
    J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting p53
    Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
    Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of NADPH homeostasis by total flavonoids from Adinandra nitida Merr. ex Li leaves triggers ROS-dependent p53 activation leading to apoptosis in non-small cell lung cancer cells.
    Lan T; He S; Luo X; Pi Z; Lai W; Jiang C; Gan J; Wei S; Wu Z; Yun C; Leng J; Li C
    J Ethnopharmacol; 2024 Oct; 332():118340. PubMed ID: 38762212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
    Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
    Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Anti-Cancer Peptide LVTX-8 Inhibits the Proliferation and Migration of Lung Tumor Cells by Regulating Causal Genes' Expression in p53-Related Pathways.
    Zhang P; Yan Y; Wang J; Dong X; Zhang G; Zeng Y; Liu Z
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32498425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide-based tumor inhibitor encoding mitochondrial p14(ARF) is highly efficacious to diverse tumors.
    Saito K; Iioka H; Kojima C; Ogawa M; Kondo E
    Cancer Sci; 2016 Sep; 107(9):1290-301. PubMed ID: 27317619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pien Tze Huang Inhibits Proliferation of Colorectal Cancer Cells through Suppressing PNO1 Expression and Activating p53/p21 Signaling Pathway.
    Cao LJ; Liu LY; Chen YQ; Han YY; Wei LH; Yao MY; Fang Y; Wu MZ; Cheng Y; Sferra TJ; Liu HX; Li L; Peng J; Shen AL
    Chin J Integr Med; 2024 Jun; 30(6):515-524. PubMed ID: 38216838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
    Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
    Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
    Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
    Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.